Company profile: Biomodal
1.1 - Company Overview
Company description
- Provider of DNA sequencing tools and multiomic solutions enabling combined genetic and epigenetic analysis from low-input DNA, distinguishing 5mC and 5hmC via duet multiomics solution evoC and +modC, which integrates assay and software for use with existing NGS pipelines; and modality, an analysis package for efficient, scalable 5- and 6-base genome analysis to inform genome organization and gene regulation.
Products and services
- Duet multiomics solution +modC: Combines the duet assay and software to analyze genetic sequences and modified cytosine simultaneously, using low-input DNA and existing next-generation sequencing pipelines, NGS-compatible
- Duet multiomics solution evoC: Delivers combined genetic and epigenetic sequence data from a single 5 ng DNA sample, distinguishing 5mC, 5hmC, and four canonical bases, single-sample
- Modality: Delivers efficient analysis of 5- and 6-base genomes, producing insights into genome organization and gene regulation, scalable
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Biomodal
Variant Bio
HQ: United States
Website
- Description: Provider of genomics-driven drug discovery, using whole-genome sequencing and custom algorithms to identify novel, population-specific variants and disease-relevant targets. Offers research partnerships, benefit-sharing programs, and an Affordable Medicines Pledge, plus the Variant Bio Standley Fellowship for genomic data analysis and partnerships with populations with specific health-related traits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Variant Bio company profile →
Genomas
HQ: United States
Website
- Description: Provider of DNA-guided medicine products that bring personalized prescription of drugs to clinical practice, targeting treatments for mental illness, diabetes, and cardiovascular disease, and aimed at eliminating trial-and-error prescribing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genomas company profile →
Tepnel Pharma Services
HQ: United Kingdom
Website
- Description: Provider of independent contract research services supporting the drug development pipeline at the Rx/Dx interface, delivering quality control laboratory analysis to help advance precision medicine and a value healthcare system that improves patient outcomes; part of a leading global healthcare and diagnostics company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tepnel Pharma Services company profile →
Genprex
HQ: United States
Website
- Description: Provider of clinical-stage immunogene therapies and diabetes gene therapy candidates: REQORSA for non-small and small cell lung cancer using the ONCOPREX nanoparticle system to deliver the TUSC2 tumor suppressor gene; GPX-002 for Type 1 Diabetes via AAV delivery of Pdx1 and MafA to convert alpha cells to beta-like cells; and GPX-003 for Type 2 Diabetes targeting beta cell replenishment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genprex company profile →
Geneseeq
HQ: Canada
Website
- Description: Provider of NGS-based genomic testing and research services for cancer care, offering pan-cancer and tumor-specific panels plus project design, sequencing and data analysis. Products include GeneseeqPrime™ (437-gene solid tumor panel with mutation, tumor mutational burden and DNA mismatch repair insights), GeneseeqPrime™ HRD for PARP inhibitor guidance, Hemasalus™ DNA/Hemarna™ RNA for hematological cancers, and Shielding™ ULTRA MRD ctDNA detection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Geneseeq company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Biomodal
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Biomodal
2.2 - Growth funds investing in similar companies to Biomodal
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Biomodal
4.2 - Public trading comparable groups for Biomodal
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →